Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects

Drug-drug Interaction Clinical Trial

Official title:

Open-Label, Two-Period Phase 1 Study in Healthy Subjects to Evaluate the Potential Effect of Multiple Doses of Paroxetine on the Pharmacokinetics and Safety of HBI-3000

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04650542
• Other study ID #: HBI-3000-401
• Status: Completed
• Phase: Phase 1
• Start date: February 21, 2021
• Est. completion date: August 13, 2021

Study information

• Verified date: July 2022
• Source: HUYABIO International, LLC.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects

Description:

This is a Phase 1 study in healthy volunteers to evaluate the potential effect of multiple doses of paroxetine on the pharmacokinetics and safety of HBI-3000. Each subject serves as his/her own control: Period 1 vs. Period 2.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 39
• Est. completion date: August 13, 2021
• Est. primary completion date: August 13, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

Healthy adult males and females

• 18 - 50 years of age

• BMI 18 - 32 kg/m2

• Subject has no clinically significant abnormality on electrocardiogram (ECG)

• Subject has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least 4 months

• Subject is willing to comply with the study restrictions, including contraception requirements

Exclusion Criteria:

• Evidence of a clinically significant disease or abnormalities, including an active, current infection or clinically significant infection within 8 weeks prior to the first dose

• Severe allergic reaction, angioedema, or anaphylaxis to drugs, or food or latex allergies

• Subject has an estimated creatinine clearance of = 70 mL

• Subject has evidence of a clinically significant deviation from normal in the physical examination, vital signs, or clinical laboratory determinations

• Subject has significant ECG abnormality, history or presence of cardiac arrhythmia or conduction abnormalities, or bradycardia (< 45 bpm)

• Subject has a history of vasovagal syncope, or symptomatic orthostatic hypotension

• Subject has as a history of or current alcohol abuse and/or other drug addiction

• Subject has received an investigational drug (including investigational vaccines) within 5 half-lives of such drug prior to Study Day 1

• Subject has received CYP2D inhibitors (e.g., fluoxetine, sertraline, duloxetine, bupropion, chloroquine, cimetidine, diphenhydramine) less than 3 weeks prior to administration of the initial dose of study drug

• Subject has suicidal thinking and behavior (suicidality) or other significant psychiatric disorders based on self-disclosure during interview (Screening visit)

• Subject has a history of acute narrow-angle glaucoma

• Subject has as any condition that would make him or her, in the opinion of the Investigator or Sponsor, unsuitable for the study

Related Conditions & MeSH terms

• Drug-drug Interaction

Intervention

Drug:
• HBI-3000
small molecule, multi-ion channel blocker
• Paroxetine
serotonin uptake inhibitor, CYP2D6 inhibitor

Locations

Country	Name	City	State
Australia	Nucleus Network Pty Ltd.	Melbourne	Victoria
United States	Spaulding Clinical	West Bend	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
HUYABIO International, LLC.

Countries where clinical trial is conducted

United States,  Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Plasma pharmacokinetics (PK): Maximum observed plasma concentration (Cmax)	To determine the plasma Cmax of a single dose of HBI 3000 administered intravenously (IV), in the absence and the presence of CYP2D6 inhibition, achieved with multiple oral doses of paroxetine, a strong CYP2D6 inhibitor, in healthy male and female subjects. Blood samples will be taken from 0 through 72 hours after the start of HBI-3000 infusion.	72 hours
Primary	Plasma pharmacokinetics (PK): Area Under the Curve (AUC) from time 0 to last measurable concentration (AUC0 - tau)	To determine the plasma AUC of a single dose of HBI 3000 administered intravenously (IV), in the absence and the presence of CYP2D6 inhibition, achieved with multiple oral doses of paroxetine, a strong CYP2D6 inhibitor, in healthy male and female subjects. Blood samples will be taken from 0 through 72 hours after the start of HBI-3000 infusion.	72 hours
Primary	Plasma pharmacokinetics (PK): Area Under the Curve (AUC) from time 0 to infinity (AUC0 - infinity), if data permits	To determine the plasma AUC of a single dose of HBI 3000 administered intravenously (IV), in the absence and the presence of CYP2D6 inhibition, achieved with multiple oral doses of paroxetine, a strong CYP2D6 inhibitor, in healthy male and female subjects. Blood samples will be taken from 0 through 72 hours after the start of HBI-3000 infusion.	72 hours
Secondary	Treatment-Emergent Adverse Events (TEAEs), including serious TEAEs	To evaluate the safety and tolerability of HBI-3000 in the absence and the presence of paroxetine, as measured by Treatment-Emergent Adverse Events (TEAEs), including serious TEAEs. TEAE is defined as follows: An AE that emerges during treatment, having been absent at pretreatment (Baseline), an AE that re emerges during treatment, having been present at pretreatment (Baseline) but stopped before treatment, or an AE that worsens in severity during treatment relative to the pretreatment state, when the AE is ongoing. TEAEs will be recorded for approximately 25 days commencing with the start of HBI-3000 infusion.	25 days
Secondary	Routine hematology and coagulation	To evaluate the safety and tolerability of HBI-3000 in the absence and the presence of paroxetine, as measured by routine hematology and coagulation tests, at Screening and periodically during the study, including: Hematocrit (Packed cell volume); Hemoglobin; Lymphocytes; Mean cell hemoglobin Mean cell hemoglobin concentration; Mean cell volume; Basophils; Eosinophils; Monocytes; Neutrophils; Platelet count; Red blood cell count; White blood cell count; Coagulation Tests; Prothrombin time; International normalised ratio; Partial thromboplastin time	25 days
Secondary	Routine serum chemistry	To evaluate the safety and tolerability of HBI-3000 in the absence and the presence of paroxetine, as measured by routine serum clinical chemistry tests, at Screening and periodically during the study, including: Alanine aminotransferase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Bicarbonate; Bilirubin (total); Bilirubin (direct); Calcium; Chloride; Cholesterol; Creatine kinase; Creatinine, estimated clearance; Gamma glutamyl transferase; Triglycerides; Globulin; A/G ratio; Glucose; Magnesium; Potassium; Phosphate (inorganic); Protein (total); Sodium; Urea; Uric acid	25 days
Secondary	Vitals signs	To evaluate the safety and tolerability of HBI-3000 in the absence and the presence of paroxetine, as measured by vitals signs including heart rate and blood pressure using an automated blood pressure device, at Screening and periodically during the study.	25 days
Secondary	12-lead ECG	To evaluate the safety and tolerability of HBI-3000 in the absence and the presence of paroxetine, as measured by 12-lead ECG. Twelve-lead ECGs will be measured at Screening and periodically during the study using standardized equipment provided by the core ECG laboratory and reviewed locally by the Investigator. QTc interval will be calculated from Fridericia's formula.	25 days
Secondary	Continuous telemetry	To evaluate the safety and tolerability of HBI-3000 in the absence and the presence of paroxetine, as measured by monitoring via a continuous cardiac telemetry monitoring system for 8 hours commencing with the start of HBI-3000 infusion	8 hours beginning at the start of infusion
Secondary	Infusion site (local) reactions	To evaluate the safety and tolerability of HBI-3000 in the absence and the presence of paroxetine, as measured by observing infusion site (local) reactions for the duration of the study (approximately 25 days) commencing with the start of HBI-3000 infusion	25 days
Secondary	Physical examination findings	To evaluate the safety and tolerability of HBI-3000 in the absence and the presence of paroxetine, as measured by examination of body systems and symptom directed examination as indicated, at Screening and during the study (approximately 25 days)	25 days
Secondary	Left ventricular ejection fraction (LVEF), Exploratory	To evaluate the safety and tolerability of HBI-3000 in the absence of paroxetine, as measured by 2D transthoracic echocardiogram to measure changes in cardiac contractility, determined at baseline and at 30 minutes and 2 hours after the start of infusion	At baseline and 2 hours beginning at the start of infusion